The results revealed that there was no significant difference between the two study arms (A vs. B) in the rate of amenorrhea development and persistence (85.7 vs. 89.5%), and in the achievement of postmenopausal estradiol (91.2 vs. 94.1%) and FSH levels (79.4 vs. 88.2%). Here, BRD2 is linked to amenorrhea.